Okay, buckle up because I’m about to tell you about one of the most bonkers stock stories of 2025. Picture this: a company with literally zero revenue somehow managed to make early investors 17,000% richer. Yes, you read that right – seventeen THOUSAND percent.
Meet Regencell Bioscience (NASDAQ: RGC), a Hong Kong-based company that’s basically the financial equivalent of that friend who somehow always lands on their feet despite making questionable life choices.
What Does This Company Actually Do?
Regencell is working on Traditional Chinese Medicine treatments for ADHD and autism. Noble cause, right? The only tiny problem is they haven’t made a single dollar in revenue since going public in 2021. Not one. Their SEC filing basically reads like a confession: “We have no saleable products and have not generated any revenue from product sales.”
In fact, they’ve been burning through cash faster than a crypto bro at a Tesla dealership – losing $3.58 million in 2025 and $4.36 million in 2024. And they’re planning to keep losing money “for the foreseeable future.” Charming!
So How Did This Stock Go to the Moon?
Here’s where it gets spicy. The company has what’s called a “low public float” – fancy talk for “there aren’t many shares available for us regular folks to buy.” The founder owns 88.6% of the company, leaving only about 56 million shares floating around for everyone else to fight over.
When you have limited supply and suddenly everyone wants in, prices go absolutely bananas. Add some algorithmic trading bots that probably got excited about the low float, sprinkle in some social media buzz about Chinese medicine curing ADHD, and boom – you’ve got yourself a rocket ship.
The stock climbed all the way to $595 per share by June. Then came the plot twist: a 38-for-1 stock split. Suddenly, instead of one $595 share, you had 38 shares at $16 each. This made the stock “cheaper” to buy (even though the total value was the same), which got more people excited and pushed it up to $70 per share.
The Reality Check
Before you start googling “how to buy Regencell stock,” pump the brakes. The Department of Justice is currently investigating the company’s trading patterns, which is never a good sign. It’s like having the principal call your parents – technically you might not be in trouble yet, but it’s probably not great news.
The stock has been on a roller coaster, crashing back down and now sitting around $23 per share. Still up thousands of percent from where it started, but way down from its peak.
The Takeaway
This is a perfect example of how markets can get absolutely wild when you mix limited supply, algorithmic trading, and good old-fashioned FOMO. Sure, some people made life-changing money, but this isn’t investing – it’s more like playing the lottery with extra steps.
If you’re thinking about jumping into stocks like this, just remember: for every person who made 17,000%, there are probably a lot more who bought at $595 and are now wondering why they didn’t just put their money in an index fund instead.